AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de los Reyes, B.
Right arrow Articles by Arenas, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de los Reyes, B.
Right arrow Articles by Arenas, J.
Agricola
Right arrow Articles by de los Reyes, B.
Right arrow Articles by Arenas, J.

American Journal of Clinical Nutrition, Vol 67, 386-390, Copyright © 1998 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Effects of L-carnitine on erythrocyte acyl-CoA, free CoA, and glycerophospholipid acyltransferase in uremia

B de los Reyes, JA Navarro, R Perez-Garcia, A Liras, Y Campos, B Bornstein and J Arenas
Centro de Investigacion, Hospital 12 de Octubre, Madrid, Spain.

We studied the effects of L-carnitine treatment in the acyl flux of erythrocyte membranes from uremic patients. We found a significantly lower relative proportion of long-chain acyl-CoA (LCCoA) to free CoA (FCoA) in patients than in control subjects. In addition, patients had reduced activities of both carnitine palmitoyltransferase (CPT) and glycerophospholipid acyltransferase (LAT; CoA dependent), and increased ratios of long-chain acylcarnitine (LCAC) to free carnitine in their erythrocytes. These data support the hypothesis that acyl-trafficking is altered in erythrocytes in uremia. After treatment with L-carnitine, we observed a significant increase in CPT and LAT activities as well as in the LCCoA-FCoA ratio, and a significant decrease in the ratio of LCAC to free carnitine. These results support the conclusion that L- carnitine supplementation improves erythrocyte flux in uremic patients.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Arduini and M. Bonomini
Reply: potential Mode of Action of L-carnitine on uraemic anaemia
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 955 - 956.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Jofre, P. Rodriguez-Benitez, J. M. Lopez-Gomez, and R. Perez-Garcia
Inflammatory Syndrome in Patients on Hemodialysis
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S274 - S280.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Arduini, M. Bonomini, E. J. Clutterbuck, M. A. Laffan, and C. D. Pusey
Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients
Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2671 - 2672.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Kitamura, K. Satoh, T. Satoh, M. Takita, and A. Matsuura
Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells
Nephrol. Dial. Transplant., May 1, 2005; 20(5): 981 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. Rodriguez-Benitez, R. Perez-Garcia, J. Arenas, F. Valderrabano, and J. Bommer
L-Carnitine in dialysis, more than a commercial affair
Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1477 - 1478.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by The American Society for Nutrition